PBCAR 269A
Alternative Names: PBCAR 269; PBCAR269ALatest Information Update: 04 Jul 2025
At a glance
- Originator Precision Biosciences
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Multiple myeloma
Most Recent Events
- 01 Jul 2025 SpringWorks Therapeutics has been acquired by Merck KGaA
- 11 Jan 2024 PBCAR 269A is available for licensing as of 09 Jan 2024. www.precisionbiosciences.com
- 21 Sep 2023 Precision Biosciences terminates a phase I/IIa trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA due to lack of sufficient therapeutic effect (NCT04171843)